Cytokinetics

Cytokinetics focuses on providing patients access to treatments that improve their lives.

Reldesemtiv, a fast skeletal muscle troponin activator (FSTA), has been evaluated in multiple clinical trials.

The page provides a form for U.S. healthcare providers to request medical information and directs patient inquiries to Cytokinetics.

-2789

Cytokinetics seeks top talent in muscle biology research to join its team.

Cytokinetics warns about fraudulent job advertisements and impersonated employment offers.

Department of Cellular and Molecular Medicine

HCM is the most common inherited cardiovascular disorder, with approximately 280,000 patients diagnosed in the U.S. Learn about HCM and see Jillian's story.

Cytokinetics has over 25 years of expertise in discovering and developing therapies for muscle performance diseases.

Heart failure affects 64 million people worldwide, and are committed to helping people living with heart failure and developing potential treatments.

There are over 600 muscles in the body that help with performing a myriad of functions, from involuntary ones like breathing to voluntary ones such as walking.

Cytokinetics develops potential medicines for diseases affecting muscle function, including its research and medicines.

Cytokinetics ensures safe, equitable access to investigational therapies for muscle diseases and outlines clinical trial policies.

Cytokinetics provides additional details on handling Consumer Health Data under U.S. state laws.

Cytokinetics explains how cookies and similar technologies collect user information.

Cytokinetics respects user privacy and outlines practices for handling personal data in its Privacy Policy.

The Terms of Use govern access to Cytokinetics’ services, applications, platforms, and websites.